President Donald Trump recently signed an executive order aimed at increasing access to psychedelic drug treatments for mental health conditions. The signing ceremony included podcaster Joe Rogan, who revealed he had previously messaged the president about research on the psychedelic ibogaine.
In this week’s STATus Report, host Alex Hogan discusses the executive order’s scope and limitations with STAT Washington correspondent Daniel Payne. Hogan also examines why ibogaine and other psychedelic drugs are gaining recognition as potential treatments for difficult-to-treat conditions, including addiction, depression, and post-traumatic stress disorder (PTSD).
Related articles
Robert F. Kennedy Jr. Balances Vaccine Skepticism with Ohio Outreach Tour
Here in Washington, we’ve been hearing about tensions between the White House and one of its most controversial — but, at least in some circles, most...
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...